KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $121.9 million.

  • Vertex Pharmaceuticals' Interest & Investment Income fell 491.42% to $121.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $490.9 million, marking a year-over-year decrease of 1792.34%. This contributed to the annual value of $490.9 million for FY2025, which is 1792.34% down from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Interest & Investment Income stood at $121.9 million, which was down 491.42% from $125.7 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Interest & Investment Income peaked at $181.2 million during Q1 2024, and registered a low of $1.1 million during Q2 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Interest & Investment Income averaged around $92.7 million, with its median value being $122.2 million (2025).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Interest & Investment Income crashed by 8807.25% in 2021 and then skyrocketed by 756250.0% in 2023.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Interest & Investment Income stood at $1.2 million in 2021, then surged by 7066.67% to $86.0 million in 2022, then surged by 108.72% to $179.5 million in 2023, then dropped by 28.58% to $128.2 million in 2024, then decreased by 4.91% to $121.9 million in 2025.
  • Its last three reported values are $121.9 million in Q4 2025, $125.7 million for Q3 2025, and $122.4 million during Q2 2025.